Outcome measures in clinical trials on medicinal products for the treatment of dementia: A European regulatory perspective

International Psychogeriatrics

Volumn 19, Issue 3, 2007, Pages 509-524

  Broich, Karl ^a,b  

^a FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES   (Germany)

^b Federal Institute for Drugs and Medical Devices   (Germany)

Author keywords

Clinical trials; Dementia; Disease modifying treatment; Drug approval; Endpoints; Outcome measures; Symptomatic treatment

Indexed keywords

CHOLINESTERASE INHIBITOR; NOOTROPIC AGENT; TAU PROTEIN;

COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; DAILY LIFE ACTIVITY; DEMENTIA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; HUMAN; MEDICINAL PLANT; MOLECULAR BIOLOGY; MULTIINFARCT DEMENTIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZATION; SELF CARE; STATISTICAL SIGNIFICANCE;

AGED; ALZHEIMER DISEASE; DRUG APPROVAL; EUROPE; HUMANS; MENTAL STATUS SCHEDULE; NOOTROPIC AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS;

EID: 34248217144     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610207005273     Document Type: Conference Paper

References (48)

1. Aguero-Torres, H. and Winblad, B. (2000). Alzheimer's disease and vascular dementia: some points of confluence. Annals of the New York Academy of Science, 903, 547-552.
2. Aisen, P. (2006). Commentary on "Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials". Alzheimer's and Dementia, 2, 272-274.
3. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders DSM-IVTR., Washington, DC: American Psychiatric Press.
4. Andreasen, N. and Blennow, K. (2005). CSF biomarkers for mild cognitive impairment and early Alzheimer's disease. Clinical Neurology and Neurosurgery, 107, 165-173.
5. Andrieu, S., Rascol, O., Lang, T., Grandjean, H. and Vellas, B. (2006). Disease modifying trials in Alzheimer disease: methodological and statistical issues. Journal of Nutrition Health and Aging, 10, 116-117.
6. Bibl, M. et al. (2006). CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain, 129, 1177-1187.
7. Blennow, K., de Leon, M. J. and Zetterberg, H. (2006). Alzheimer's disease. Lancet, 368, 387-403.
8. Burns, A. et al. (2006). Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. Journal of Psychopharmacology, 20, 732-755.
9. Chong, M. S., Lim, W. S. and Sahadevan, S. (2006). Biomarkers in preclinical Alzheimer's disease. Current Opinion Investigational Drugs, 7, 600-607.
10. Coimbra, A., Williams, D. S. and Hostetler, E. D. (2006). The role of MRI and PET/SPECT in Alzheimer's disease. Current Topical Medical Chemistry, 6, 629-647.
11. Cummings, J. L. (2005). Clinical evaluation as a biomarker for Alzheimer's disease. Journal of Alzheimer's Disease, 8, 327-337.
12. Cummings, J. (2006). Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimer's and Dementia, 2, 263-271.
13. de Leon, M. J. et al. (2004). MRI and CSF studies in the early diagnosis of Alzheimer's disease. Journal of Internal Medicine, 256, 205-223.
14. Demers, L., Oremus, M., Perrault, A., Champoux, N. and Wolfson, C. (2000). Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of functional and quality of life scales. Journal Geriatric Psychiatry and Neurology, 13, 170-180.
15. Dickerson, B. C. and Sperling, R. A. (2005). Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx, 2, 348-360.
16. Doraiswamy, P. M., Bieber, F., Kaiser, L., Krishnan, K. R., Reuning-Scherer, J. and Gulanski, B. (1997). The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology, 48, 1511-1517.
17. Engler, H. et al. (2006). Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain, 129, 2856-2866.
18. Feldman, H. et al. (2001). The disability assessment for dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer disease. Alzheimer Disease and Associated Disorders, 15, 89-95.
19. Ferris, S. H. (2003). General measures of cognition. International Psychogeriatrics, 15 (Suppl. 1), 215-217.
20. Galasko, D., Schmitt, F., Thomas, R., Jin, S. and Bennett, D. (2005). Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. Journal of the International Neuropsychology Society, 11, 446-453.
21. Ganguli, M. (2006). Mild cognitive impairment and the 7 uses of epidemiology. Alzheimer's Disease and Associated Disorders, 20, S52-S57.
22. Gauthier, S. (2006). Functional outcomes. In K. Rockwood and S. Gauthier (eds.), Trial Designs and Outcomes in Dementia Therapeutic Research (pp. 113-118). London: Taylor & Francis.
23. Kluft, C. (2004). Principles of use of surrogate markers and endpoints. Maturitas, 47, 293-298.
24. Mani, R. B. (2004). The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Statistics in Medicine, 23, 305-314.
25. McKeith, I. G. et al. (2005). Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology, 65, 1863-1872.
26. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. and Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34, 939-944.
27. Miyasaki, J. M. et al. (2006). Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 7, 996-1002.
28. Mohs, R. C. et al. (1997). Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer's Disease and Associated Disorders, 11 (Suppl. 2), S13-S21.
29. Nadkarni, N. and Black, S. (2006). Cognitive outcomes. In K. Rockwood and S. Gauthier (eds.), Trial Designs and Outcomes in Dementia Therapeutic Research (pp. 85-112). London: Taylor & Francis.
30. Nordberg, A. (2004). PET imaging of amyloid in Alzheimer's disease. Lancet Neurology, 3, 519-527.
31. Nygard, L. (2003). Instrumental activities of daily living: a stepping-stone towards Alzheimer's disease diagnosis in subjects with mild cognitive impairment? Acta Neurologica Scandinavica Supplementum, 179, 42-46.
32. Nygard, L. and Winblad, B. (2006). Measuring long-term effects and changes in the daily activities of people with dementia. Journal of Nutrition Health Aging, 10, 137-138.
33. Oremus, M., Perrault, A., Demers, L. and Wolfson, C. (2000). Review of outcome measurement instruments in Alzheimer's disease drug trials: psychometric properties of global scales. Journal of Geriatric Psychiatry and Neurology, 13, 197-205.
34. Perneczky, R. et al. (2006). Complex activities of daily living in mild cognitive impairment: conceptual and diagnostic issues. Age and Ageing, 35, 240-245.
35. Petersen, R. C. and Knopman, D. S. (2006). MCI is a clinically useful concept. International Psychogeriatrics, 18, 394-402.
36. Pupi, A., Mosconi, L., Nobili, F. M. and Sorbi, S. (2005). Toward the validation of functional neuroimaging as a potential biomarker for Alzheimer's disease: implications for drug development. Molecular Imaging Biology, 7, 59-68.
37. Ritchie, K. and Lovestone, S. (2002). The dementias. Lancet, 360, 1759-1766.
38. Rockwood, K. (2003). Mixed dementia: Alzheimer's and cerebrovascular disease. International Psychogeriatrics, 15 (Suppl. 1), 39-46.
39. Rockwood, K. (2006a). Global Assessment Measures. In K. Rockwood and S. Gauthier (eds.), Trial Designs and Outcomes in Dementia Therapeutic Research (pp. 75-84). London: Taylor & Francis.
40. Rockwood, K. (2006b) Quality of life outcomes. In K. Rockwood and S. Gauthier (eds.), Trial Designs and Outcomes in Dementia Therapeutic Research (pp. 131-140). London: Taylor & Francis.
41. Román, G. C. et al. (1993). Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology, 43, 250-260.
42. Shin, I. S., Carter, M., Masterman, D., Fairbanks, L. and Cummings, J. L. (2005). Neuropsychiatric symptoms and quality of life in Alzheimer disease. American Journal of Geriatric Psychiatry, 13, 469-474.
43. Standish, T. I., Molloy, D. W., Bedard, M., Layne, E. C., Murray, E. A. and Strang, D. (1996). Improved reliability of the Standardized Alzheimer's Disease Assessment Scale (SADAS) compared with the Alzheimer's Disease Assessment Scale (ADAS). Journal of the American Geriatrics Society, 44, 712-716.
44. Talwalker, S., Overall, J. E., Srirama, M. K. and Gracon, S. I. (1996). Cardinal features of cognitive dysfunction in Alzheimer's disease: a factor-analytic study of the Alzheimer's Disease Assessment Scale. Journal of Geriatric Psychiatry and Neurology, 9, 39-46.
45. Vellas, B., Andrieu, S., Sampaio, C. and Wilcock, G. (2007). Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurology, 6, 56-62.
46. Visser, P. J. and Brodaty, H. (2006). MCI is not a clinically useful concept. International Psychogeriatrics, 18, 402-409.
47. Whitehouse, P. J., Patterson, M. B. and Sami, S. A. (2003). Quality of life in dementia: ten years later. Alzheimer Disease and Associated Disorders, 17, 199-200.
48. World Health Organization (2007). The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: World Health Organization.